Bio-Rad Laboratories (NYSE:BIO.B) Trading Down 4.7% – Time to Sell?

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO.B) were down 4.7% during mid-day trading on Tuesday . The company traded as low as $289.23 and last traded at $290.00. 818 shares were traded during trading, an increase of 5,282% from the average daily volume of 15 shares. The stock had previously closed at $304.15.

Bio-Rad Laboratories Price Performance

The stock has a fifty day moving average of $286.39 and a two-hundred day moving average of $289.44. The stock has a market cap of $7.93 billion, a price-to-earnings ratio of 48.85 and a beta of 0.95. The company has a quick ratio of 2.37, a current ratio of 3.21 and a debt-to-equity ratio of 0.12.

Bio-Rad Laboratories (NYSE:BIO.B) last released its earnings results on Thursday, April 30th. The company reported $1.89 EPS for the quarter. Bio-Rad Laboratories had a return on equity of 3.56% and a net margin of 6.52%.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of innovative products and systems that serve the life science research and clinical diagnostics markets. The company operates through two primary segments: Life Science, which delivers instruments, consumables and software for research applications, and Clinical Diagnostics, which offers quality control materials and reagent systems for blood typing, immunology and molecular testing. Bio-Rad’s product portfolio supports a wide range of applications, including protein analysis, gene expression, cell biology and digital PCR.

In the Life Science segment, Bio-Rad develops and markets technologies such as electrophoresis and imaging systems, chromatography instruments, laboratory consumables and software platforms that streamline experimental workflows.